European Union - English - EMA (European Medicines Agency)

teva pharma b.v. - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - combinations - clopidogrel/acetylsalicylic acid teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (asa). clopidogrel/acetylsalicylic acid teva is a fixed‑dose combination medicinal product for continuation of therapy in:non‑st segment elevation acute coronary syndrome (unstable angina or non‑q‑wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionst segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

European Union - English - EMA (European Medicines Agency)

mylan pharmaceuticals limited - acetylsalicylic acid, clopidogrel hydrogen sulfate - acute coronary syndrome; myocardial infarction - antithrombotic agents - clopidogrel/acetylsalicylic acid mylan is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (asa).clopidogrel/acetylsalicylic acid mylan is a fixed-dose combination medicinal product for continuation of therapy in:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionst segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

European Union - English - EMA (European Medicines Agency)

sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antithrombotic agents - acute coronary syndromemyocardial infarction

Malta - English - Medicines Authority

billev pharma aps fuglebækgaard, elmegårdsvej 1a, tørslev, 3630 jægerspris, denmark - clopidogrel, acetylsalicylic acid - film-coated tablet - clopidogrel 75 mg acetylsalicylic acid 75 mg - antithrombotic agents

Malta - English - Medicines Authority

billev pharma aps fuglebækgaard, elmegårdsvej 1a, tørslev, 3630 jægerspris, denmark - clopidogrel, acetylsalicylic acid - film-coated tablet - clopidogrel 75 mg acetylsalicylic acid 100 mg - antithrombotic agents

European Union - English - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antithrombotic agents - duoplavin is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.for further information please refer to section 5.1.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - (acetylsalicylic acid layer) acetylsalicylic acid (as acetylsalicylic acid granulated with starch); (clopidogrel layer) clopidogrel (as clopidogrel hydrogen sulfate form ii) - tablet, film coated - 100 mg - (acetylsalicylic acid layer) acetylsalicylic acid (as acetylsalicylic acid granulated with starch) 100 mg; (clopidogrel layer) clopidogrel (as clopidogrel hydrogen sulfate form ii) 75 mg

European Union - English - EMA (European Medicines Agency)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.adult patients suffering from acute coronary syndrome.non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event.prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.for further information please refer to section 5.1.

European Union - English - EMA (European Medicines Agency)

zentiva k.s. - clopidogrel - stroke; peripheral vascular diseases; myocardial infarction; acute coronary syndrome - antithrombotic agents - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.for further information please refer to section 5.1.

Israel - English - Ministry of Health

bayer israel ltd - acetylsalicylic acid; ascorbic acid - tablets effervescent - acetylsalicylic acid 400 mg; ascorbic acid 240 mg - acetylsalicylic acid - acetylsalicylic acid - pain relief, fever reduction, antirheumatic treatment.